Regeneron (REGN) Beats on Q2 Earnings, Updates 2015 View – Tale of the Tape
Regeneron Pharmaceuticals (REGN) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions. The Tarrytown, NY based company has four FDA approved products – Arcalyst, Eylea, Praluent and Zaltrap in its portfolio.
Regeneron is most well-known for its eye drug Eylea, which performed well during the quarter. Regeneron received a major boost when its PCSK9 inhibitor, Praluent for the treatment of high LDL cholesterol in adults gained approval in the U.S. The cholesterol management market represents huge commercial potential and Praluent is expected to generate blockbuster sales.
The company has recorded positive earnings surprises in one of the trailing four quarters with an average miss of 11.84%.